Literature DB >> 32385646

[68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with hepatic cancer.

Jieling Zheng1, Shaobo Yao2.   

Abstract

Entities:  

Year:  2020        PMID: 32385646     DOI: 10.1007/s00259-020-04847-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  4 in total

1.  68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT.

Authors:  Chunxia Qin; Fuqiang Shao; Yongkang Gai; Qingyao Liu; Weiwei Ruan; Fang Liu; Fan Hu; Xiaoli Lan
Journal:  J Nucl Med       Date:  2021-04-16       Impact factor: 11.082

Review 2.  Clinical Results of Fibroblast Activation Protein (FAP) Specific PET and Implications for Radiotherapy Planning: Systematic Review.

Authors:  Paul Windisch; Daniel R Zwahlen; Stefan A Koerber; Frederik L Giesel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  Cancers (Basel)       Date:  2020-09-15       Impact factor: 6.639

Review 3.  Clinical results of fibroblast activation protein (FAP) specific PET for non-malignant indications: systematic review.

Authors:  Paul Windisch; Daniel R Zwahlen; Frederik L Giesel; Eberhard Scholz; Patrick Lugenbiel; Jürgen Debus; Uwe Haberkorn; Sebastian Adeberg
Journal:  EJNMMI Res       Date:  2021-02-19       Impact factor: 3.138

4.  Equivalent tumor detection for early and late FAPI-46 PET acquisition.

Authors:  J Ferdinandus; L Kessler; N Hirmas; M Trajkovic-Arsic; R Hamacher; L Umutlu; M Nader; F Zarrad; M Weber; W P Fendler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-23       Impact factor: 9.236

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.